Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06389877 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

A Phase 1 study of Alpha-1 Antitrypsin Deficiency, sponsored by Beam Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
106
Enrollment target
11
Study locations

NCT06389877 is a Phase 1 study of Alpha-1 Antitrypsin Deficiency that is actively recruiting participants, run by Beam Therapeutics. The registered enrollment target is 106 participants, below the 3,072-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06389877, a Phase 1 study of Alpha-1 Antitrypsin Deficiency, is actively recruiting participants, sponsored by Beam Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
106 participants
Enrollment target
11
Study locations

Study Summary

This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD).

Conditions Studied

Alpha-1 Antitrypsin Deficiency

Interventions

  • DRUG BEAM-302

Study Locations (11)

Other

  • Clinical Study Center - Adelaide
  • Clinical Study Center - Fitzroy
  • Clinical Study Center - Dublin
  • Clinical Study Center - Leiden
  • Clinical Study Center - Auckland
  • Clinical Study Center - Hamilton
  • Clinical Study Center - London
  • Clinical Study Center - Southampton

Alabama

  • Clinical Study Center - Birmingham

Massachusetts

  • Clinical Study Center - Boston

South Carolina

  • Clinical Study Center - Charleston

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2024-06-19
Est. Completion 2030-05
Phase Phase 1

Sponsor

Beam Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06389877

The ClinicalTrials.gov registry entry for NCT06389877 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,072-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (97% lower). The listed sponsor is Beam Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 1 intervention - of which BEAM-302 is the first listed.

NCT06389877 reports 11 study locations spanning 4 distinct geographic areas - top geographies include Other, Alabama, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06389877 about?

NCT06389877 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)". This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD...

What is the current status of trial NCT06389877?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2024-06-19. Estimated completion is 2030-05.

What conditions does trial NCT06389877 study?

This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.

What interventions are being tested in trial NCT06389877?

The interventions under investigation include: BEAM-302 (DRUG).

Who is sponsoring clinical trial NCT06389877?

This trial is sponsored by Beam Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06389877 being conducted?

This trial has 11 study locations across Alabama, Massachusetts, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alpha-1 Antitrypsin Deficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alpha-1 Antitrypsin Deficiency

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.